Literature DB >> 23718817

Bridge to recovery or permanent system implantation: an eight-year single-center experience in transvenous semipermanent pacing.

Angela Kornberger1, Eckhard Schmid, Guenay Kalender, Ulrich Alfred Stock, Volker Doernberger, Mahmud Khalil, Milan Lisy.   

Abstract

BACKGROUND: To compare the risks, implications, and outcomes of transvenous semipermanent pacing as a bridge to permanent system implantation or recovery.
METHODS: We investigated semipermanent transvenous pacing systems consisting of one (n = 57%) or two (n = 3%) bipolar active-fixation pacing leads and an attached epicutaneous pulse generator implanted from 2000 to 2009. The study population comprised 60 patients aged 72.9 ± 10.5 years (44 [73.3%] male). Forty-two (70%) were enrolled for complete system explantation for cardiac-implanted electronic devices associated infection. Eighteen (30%) required temporary pacing in the context of a variety of mostly severe cardiac and noncardiac conditions. The semipermanent pacing systems were removed after implantation of permanent systems or recovery of a noncompromising heart rhythm, respectively.
RESULTS: Transvenous semipermanent lead implantation was successful in 59 (98.3%) patients. Major and minor intraoperative complications occurred in one case (1.7%) each. The semipermanent systems were left in situ for a mean period of 14.6 ± 8.1 days). They served as a bridge to permanent system implantation in 68.3% (n = 41) and as a bridge to recovery of a noncompromising heart rhythm in 11.7% (n = 7). Four patients (8.3%) died with the semipermanent pacing system in situ, and seven (11.7%) were transferred to external hospitals with semipermanent pacing systems.
CONCLUSIONS: Transvenous semipermanent pacing with bipolar active-fixation leads and epicutaneous pulse generators provide an important option for prolonged temporary pacing as a bridge to permanent system implantation or recovery. ©2013, The Authors. Journal compilation ©2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  implantable cardioverter defibrillator; infection; lead failure; temporary pacing

Mesh:

Year:  2013        PMID: 23718817     DOI: 10.1111/pace.12175

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  4 in total

1.  Permanent-temporary pacemakers in the management of patients with conduction abnormalities after transcatheter aortic valve replacement.

Authors:  Derek Leong; Ali A Sovari; Ashkan Ehdaie; Tarun Chakravarty; Qiang Liu; Hasan Jilaihawi; Rajendra Makkar; Xunzhang Wang; Eugenio Cingolani; Michael Shehata
Journal:  J Interv Card Electrophysiol       Date:  2018-03-12       Impact factor: 1.900

2.  Heart block and acute kidney injury due to hyperparathyroidism-induced hypercalcemic crisis.

Authors:  Taylor C Brown; James M Healy; Mary J McDonald; Joni H Hansson; Courtney E Quinn
Journal:  Yale J Biol Med       Date:  2014-12-12

3.  European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS).

Authors:  Carina Blomström-Lundqvist; Vassil Traykov; Paola Anna Erba; Haran Burri; Jens Cosedis Nielsen; Maria Grazia Bongiorni; Jeanne Poole; Giuseppe Boriani; Roberto Costa; Jean-Claude Deharo; Laurence M Epstein; Laszlo Saghy; Ulrika Snygg-Martin; Christoph Starck; Carlo Tascini; Neil Strathmore
Journal:  Europace       Date:  2020-04-01       Impact factor: 5.214

Review 4.  A Review of Temporary Permanent Pacemakers and a Comparison with Conventional Temporary Pacemakers.

Authors:  Keith Suarez; Javier E Banchs
Journal:  J Innov Card Rhythm Manag       Date:  2019-05-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.